BALTIMORE, Aug. 14, 2014 /PRNewswire/ -- AmeritoxSM, the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug Seroquel XR, one of the 40 best-selling medications in the U.S. This new method marks a critical step toward building a comprehensive reference database, providing behavioral health clinicians help in addressing the acute problem of medication non-adherence in those with serious mental illness.
Ameritox's Ingenuity Health service conducted research that allows it to provide additional information about whether a patient may be taking Seroquel XR correctly. By comparing normalized urine drug results against the results of patients clinically assessed as adherent, behavioral health centers and medical professionals will have more information as they manage and treat patients prescribed Seroquel XR.
"The singular problem of a lack of insight into whether a person is taking the medication prescribed has long been a barrier to helping those with serious mental illness," said Mike DeGeorge, Director of Medical Affairs for Ameritox and Ingenuity Health. "This method helps address the problem that behavioral health clinicians face with 50 percent of their patients: medication non-adherence."
Seroquel XR, a branded form of quetiapine, is the second antipsychotic medication for which Ingenuity Health has established a reference range for better assessing medication adherence. In March, Ingenuity Health introduced a reference range for Abilify, the nation's top-selling medication.
In developing these reference ranges, Ingenuity Health is building a database for comparing a patient's urine drug test results with those of a group of patients clinically assessed as adherent and taking the same medication. This database will expand Ameritox's exclusive Rx Guardian CDSM, which goes beyond traditional data gathering to provide analysis that can help clinicians address the growing problem of pain medication misuse, abuse and diversion.
Additional research is underway to develop similar reference ranges for other commonly prescribed antipsychotics.
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation's trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.
Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Watch Ameritox on YouTube: www.youtube.com/ameritox
Copyright©2014 PR Newswire.
All rights reserved